A novel HVEM-Fc recombinant protein for lung cancer immunotherapy
Our data demonstrate that HVEM-Fc exerts a strong signal that augments and prolongs T-cell activity in both murine models and human NSCLC organoid models. Moreover, the combination of HVEM-Fc with a PD-1 inhibitor yields the most effective anti-tumor outcomes.
Authors
- Wen Gao (ORCID: https://orcid.org/0000-0003-0077-4236)
- Chunji Chen (ORCID: https://orcid.org/0000-0003-0587-7680)
- Bin Li (ORCID: https://orcid.org/0009-0000-2588-2589)
- Jing Wang (ORCID: https://orcid.org/0000-0001-7110-4841)
- Chunguang Li (ORCID: https://orcid.org/0000-0002-4788-4806)
- Yu Yao
Institutions
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Shanghai Chest Hospital (CN)
- Huadong Hospital (CN)
- Shanghai Cancer Institute (CN)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1186/s13046-025-03324-8
- Citations
- 7
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 5.58